Literature DB >> 19758200

HLA-B27 and HLA-B51 determination in Tunisian healthy subjects and patients with suspected ankylosing spondylitis and Behçet's disease.

Nabil Sakly1, Radhia Boumiza, Saoussen Zrour-Hassen, Amira Hamzaoui, Salim Ben Yahia, Hamida Amara, Moncef Khairallah, Sylvia Mahjoub, Naceur Bergaoui, Ibtissem Ghedira.   

Abstract

The aim of this retrospective study is to assess the frequency of HLA-B27 and HLA-B51 in healthy subjects from the center of Tunisia and to investigate their usefulness in the diagnosis of ankylosing spondylitis (AS) and Behçet's disease (BD), respectively. Microlymphocytotoxicity test was used to perform serologic HLA typing in a group of 124 healthy volunteers and a group of 365 patients suffering from clinical manifestations of AS and/or BD. HLA-B27 was found in 3.2% of healthy subjects and in 42.9% of patients with AS (P < 0.00006). HLA-B51 is, however, found in 16.1% of healthy subjects and in 30.0% of patients with BD (P > 0.05). Unlike HLA-B51, which seems to be as frequent in Tunisian patients with BD as in healthy subjects, HLA-B27 is more frequent in patients with AS than in controls. This highlights the usefulness of HLA-B27, rather than that of HLA-B51, in the diagnosis of the respective diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19758200     DOI: 10.1111/j.1749-6632.2009.04756.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

1.  Genetic origin of Behçet's disease population in Denizli, Turkey; population genetics data analysis; historical demography and geographical perspectives based on β-globin gene cluster haplotype variation.

Authors:  O Ozturk; S Arikan; A Bahadir; A Atalay; E O Atalay
Journal:  Genes Immun       Date:  2016-12-29       Impact factor: 2.676

2.  Registry of the clinical characteristics of spondyloarthritis in a cohort of Egyptian population.

Authors:  M Y Tayel; E Soliman; W F El Baz; A El Labaan; Y Hamaad; M H Ahmed
Journal:  Rheumatol Int       Date:  2011-08-31       Impact factor: 2.631

3.  Neuro-Behçet's disease: a report of sixteen patients.

Authors:  Radi Shahien; Abdalla Bowirrat
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-25       Impact factor: 2.570

4.  Musculoskeletal Findings in Behcet's Disease.

Authors:  Ali Bicer
Journal:  Patholog Res Int       Date:  2011-09-25

5.  Prevalence of HLA-B27 in Patients with Ankylosing Spondylitis in Qatar.

Authors:  M H Abdelrahman; S Mahdy; I A Khanjar; A M Siam; H A Malallah; S A Al-Emadi; H A Sarakbi; M Hammoudeh
Journal:  Int J Rheumatol       Date:  2012-04-04

6.  Coexistence of Behçet's disease with ankylosing spondylitis and familial Mediterranean fever: a rare occurrence.

Authors:  Makram Frigui; Manel Kechaou; Moez Jallouli; Neila Kaddour; Habiba Bouhamed Chaabouni; Zouhir Bahloul
Journal:  Clin Pract       Date:  2011-05-06

Review 7.  HLA B27 antigen in Middle Eastern and Arab countries: systematic review of the strength of association with axial spondyloarthritis and methodological gaps.

Authors:  Nelly Raymond Ziade
Journal:  BMC Musculoskelet Disord       Date:  2017-06-29       Impact factor: 2.362

8.  Frequency of HLA-B5, HLA-B51 and HLA-B27 in patients with idiopathic uveitis and Behçet's disease: a case-control study.

Authors:  Saeedeh Shenavandeh; Keramat Allah Jahanshahi; Elham Aflaki; Alireza Tavassoli
Journal:  Reumatologia       Date:  2018-05-09

9.  The LMP2 CfoI polymorphism is associated with ankylosing spondylitis (AS) risk but not with acute anterior uveitis (AAU): A meta-analysis.

Authors:  Yufeng Qian; Bingqian Chen; Xiaowen Sheng; Yuqin Peng
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

10.  The association of human leukocyte antigen polymorphisms with disease severity and latency period in patients with silicosis.

Authors:  Hasan Dogan; Metin Akgun; Omer Araz; Elif Yilmazel Ucar; Ozgur Yoruk; Eda Diyarbakir; Omer Atis; Fatih Akdemir; Hamit Acemoglu; Ibrahim Pirim
Journal:  Multidiscip Respir Med       Date:  2014-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.